Monte Rosa Therapeutics (GLUE) Enterprise Value (2021 - 2026)

Monte Rosa Therapeutics' Enterprise Value history runs 7 years deep, the most recent figure standing at -$678.1 million for Q1 2026.

• In Q1 2026, Enterprise Value fell 763.48% year-over-year to -$678.1 million; the TTM figure through Mar 2026 stood at -$678.1 million (down 763.48% YoY), while the FY2025 annual figure was -$129.9 million, up 65.91% from the prior year.
• Enterprise Value for Q1 2026 stood at -$678.1 million, down from -$129.9 million in the prior quarter.
• The five-year high for Enterprise Value was -$47.0 million in Q2 2023, with the low at -$678.1 million in Q1 2026.
• The 5-year median for Enterprise Value is -$113.4 million (2022), against an average of -$176.6 million.
• The sharpest annual moves came in 2022 and 2026: Enterprise Value soared 83.86% in 2022, then tumbled 763.48% in 2026.
• Monte Rosa Therapeutics' Enterprise Value stood at -$55.9 million in 2022, then tumbled by 129.28% to -$128.1 million in 2023, then slumped by 197.39% to -$381.0 million in 2024, then soared by 65.91% to -$129.9 million in 2025, then tumbled by 422.08% to -$678.1 million in 2026.
• Business Quant data shows GLUE's Enterprise Value at -$678.1 million in Q1 2026, -$129.9 million in Q4 2025, and -$401.6 million in Q3 2025.